 | Up a level |
Journal Article
Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al Sawaf, O., Langerbeins, P., Engelke, A., Fink, A. -M., Fischer, K., Seiler, T., von Weikersthal, L. Fischer, Hebart, H., Kreuzer, K. -A., Ritgen, M., Kneba, M., Wendtner, C. -M., Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2017). BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). Haematologica, 102. S. 171 - 173. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Haas, M., Waldschmidt, D. T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., von Weikersthal, L. Fischer, Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C. B., Held, S., Von Bergwelt-Baildon, M., Boeck, S. and Heinemann, V (2021). Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method. Eur. J. Cancer, 146. S. 95 - 107. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Perkhofer, L., Striefler, J. K., Sinn, M., Opitz, B., Goetze, T. O., Gallmeier, E., von Weikersthal, L. Fischer, Jacobasch, L., Waldschmidt, D., Niedermeier, M., Sohm, M., Sookthai, D., Berger, A., Beutel, A., Seufferlein, T. and Ettrich, T. J. (2021). Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group. Ann. Oncol., 32. S. S1282 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041